FDA Reviewing Treatment for Aggressive Prostate Cancer

The Federal Drug Administration is reviewing approval of enzalutamide, a drug which lowered the risk of metastasis or death in men with non-metastatic hormone-resistant prostate cancer, according to a new study...Photo Credit: Getty Images